Puretech Health Plc Stock Today
| PRTC Stock | USD 17.46 0.15 0.85% |
PerformanceMild
| Odds Of DistressLow
|
PureTech Health is trading at 17.46 as of the 13th of February 2026, a 0.85 percent decrease since the beginning of the trading day. The stock's open price was 17.61. PureTech Health has about a 20 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 15th of November 2025 and ending today, the 13th of February 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of November 2020 | Category Healthcare | Classification Health Care |
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company has 24.17 M outstanding shares of which 3.86 K shares are at this time shorted by private and institutional investors with about 1.36 trading days to cover. More on PureTech Health PLC
Moving together with PureTech Stock
Moving against PureTech Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
PureTech Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CoFounder President | Eric Elenko | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Tel Aviv 90, Tel Aviv 125, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBy employing borrowed capital, PureTech Health can potentially magnify investment returns. Examining the debt-to-assets ratio offers investors perspective on PureTech Health's use of financial leverage and reveals what portion of PureTech Health's asset base relies on creditor financing.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PureTech Health PLC (PRTC) is traded on NASDAQ Exchange in USA and employs 56 people. PureTech Health is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 421.98 M. PureTech Health PLC conducts business under Biotechnology sector and is part of Health Care industry. The entity has 24.17 M outstanding shares of which 3.86 K shares are at this time shorted by private and institutional investors with about 1.36 trading days to cover.
PureTech Health PLC currently holds about 368.03 M in cash with (134.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.84.
Check PureTech Health Probability Of Bankruptcy
Ownership AllocationPureTech Health owns a total of 24.17 Million outstanding shares. Roughly 99.58 pct. of PureTech Health outstanding shares are held by general public with 0.42 (%) by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check PureTech Ownership Details
PureTech Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Birch Hill Investment Advisors Llc | 2025-06-30 | 242.7 K | |
| Pentwater Capital Management Lp | 2025-06-30 | 50 K | |
| Portolan Capital Management, Llc | 2025-06-30 | 27.8 K | |
| Millennium Management Llc | 2025-06-30 | 23.9 K | |
| Diadema Partners Lp | 2025-06-30 | 7.3 K | |
| Persistent Asset Partners Limited | 2025-06-30 | 1.7 K | |
| Atlantic Union Bankshares Corp | 2025-06-30 | 115 | |
| Ubs Group Ag | 2025-06-30 | 20.0 | |
| Morgan Stanley - Brokerage Accounts | 2025-06-30 | 0.0 |
PureTech Health Historical Income Statement
PureTech Stock Against Markets
PureTech Health Corporate Management
| Frank Salisbury | Senior Strategy | Profile | |
| Michael Chen | Chief Seaport | Profile | |
| Anita JD | Senior Property | Profile | |
| Lauren MBA | Chief Officer | Profile | |
| RDN MS | Chief Officer | Profile | |
| David Elmaleh | CoFounder Advisor | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PureTech Health PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Will Biotechnology sector continue expanding? Could PureTech diversify its offerings? Factors like these will boost the valuation of PureTech Health. Anticipated expansion of PureTech directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every PureTech Health data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.615 | Earnings Share 1.7 | Revenue Per Share | Quarterly Revenue Growth 5.427 | Return On Assets |
The market value of PureTech Health PLC is measured differently than its book value, which is the value of PureTech that is recorded on the company's balance sheet. Investors also form their own opinion of PureTech Health's value that differs from its market value or its book value, called intrinsic value, which is PureTech Health's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because PureTech Health's market value can be influenced by many factors that don't directly affect PureTech Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between PureTech Health's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding PureTech Health should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, PureTech Health's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.